The Ireland-based firm said that the financing will support clinical trials of an HIV test and help the company to strengthen its product pipeline.

The company is targeting its RPPA-based testing to biopharma firms as well as for clinical trial work and to clinicians to help guide therapy in cancer patients.

The firm executed contracts for 11 T2Dx instruments in the quarter and saw its sepsis test panel revenue increase 42 percent.

Last week, readers were most interested in a story about a new respiratory test launched by Roche leveraging a new PCR technology.